Abstract
Over the last two decades global pharmaceutical production has been shaped by a series of profound political, legal and economic changes.1 On the one hand, the rise of bulk pharmaceutical production in Asia and a wave of mergers and acquisitions throughout the 1990s (Kesic, 2009; Nolan, 2001) has resulted in sector concentration (Abbott and Dukes, 2009; ‘t Hoen, 2009). On the other hand, industry consolidation has been compounded by increasing standardization of intellectual property law. One hundred and fifty-three countries now adhere to the World Trade Organization’s (WTO) Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). The Agreement’s standard for intellectual property rights (IPR) has been implemented in most developing countries, with significant implications for diffusion of innovation and the range of public health policy options available to local governments. As these global processes have been under way, nation-states have grappled with how to apply new international standards, create fair domestic regulatory frameworks that maintain sufficient levels of competition in the pharmaceutical sector, and ensure access to medicine for their citizens.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Abbott, M. F. and G. Dukes (2009) Global Pharmaceutical Policy (London and New York: Edward Elgar).
Almeida, E. N. D. (2009) ‘Analise do trabalho de qualificação de fornecedores de insumos farmacêuticos na unidade de Farmanguinhos’, Masters Thesis in Public Health, FIOCRUZ, Rio de Janeiro, Brazil.
Amann, E. (2000) Economic Liberalisation and Industrial Performance in Brazil (New York: Oxford University Press).
Amin, T. (2010) ‘Re-visiting the Patents and Access to Medicines Dichotomy: An Evaluation of TRIPs Implementation and Public Health Safeguards in Developing Countries’. In Yu, O. Aginam and J. Harrington (eds) Global Governance of HIV/AIDS: Intellectual Property and Access to Essential Medicines (London: Edward Elgar).
ANVISA, (2009) ‘Medicamentos Genéricos.’ July, http://portal.anvisa.gov.br/wps/ content/Anvisa + Portal/Anvisa/Inicio/Medicamentos/Assunto + de + Interesse/Medicamentos + genericos/wps/%20content/Anvisa%E2%80%89+%E2%80%89Portal/Anvisa/Inicio/Medicamentos/Assunto%E2%80%89+%E2%80%89de%E2%80%89+%E2%80%89Interesse/Medicamentos%E2%80%89+%E2%80%89genericos, accessed September 2012.
Associação Brasileira Interdisciplinar de Aids (2009) ‘Perguntas e respostas sobre patentes pipeline: Como afetam sua saúde’, Policy paper (Rio de Janeiro ABIA).
Azevedo, R. (2010). ‘Brasil ataca acordo de ricos contra falsificação’, Estadão line, http://www.estadao.com.br/noticias/impresso,brasil-ataca-acordo-de-ricos-contrafalsificacao, 621618,0.htm/noticias/impresso,brasil-ataca-acordo-de-ricos-contrafalsificacao,%20621618,0.htm, date accessed 10 November 2010.
Barbosa, D. (2009) ‘O papel da ANVISA na concessão de patentes’,http://denisbarbosa.addr.com/papelanvisa.pdf, date accessed 3 December 2010.
Basso, M., B. Edson, J. Rodriguez (2011) Intellectual Property Law in Brazil (The Netherlands: Kluwer Law International).
Bezerra, C. A. (2006) GeneralManager of Medicines, ANVISA, Personal interview, Brasilia, 24 June.
Bird, R. (2009) ‘Developing Nations and the Compulsory Licence: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects’, Journal of Law, Medicine and Ethics, 37: 209–21.
Blatt, C. R, S. C Trauthman, E. H. Schmidt, S. Marchesan, L. M. da Silva, and J. L. Martins (2012) ‘Conhecimento Popular e Utilização dos Medicamentos Genéricos na População do Município de Tubarão, SC, Ciênc. saúde coletiva, 17: 79–87.
Cassier, M. and C. M. Correa (2003) ‘Patents, Innovation and Public Health: Brazilian Public-Sector Laboratories’ Experience in Copying AIDS Drugs’ in J.-P. Moattli, B. Coriat, Y. Soutryran, T. Barnett, J. Dumoulin and V.-A. Fiori (eds) Economics of AIDS and Access to HIV/AIDS Care in Developing Countries, Issues and Challenges (Paris: Agence Nationale de Recherches sur le Sida).
Chakraborty, S. and A. Singhvi (2009) ‘Compulsory Licensing for Access to Medicines in the Developing World’, International Journal of Intellectual Property Management, 3, 110–26.
Chequer, P. (2005) ‘Access to Treatment and Prevention: Brazil and Beyond’, Power point presentation to the International Aids Society 2005 Conference, Rio de Janeiro, http://www.aids.gov.br/en/publicacao/access-treatment-and-preventionbrazil-and-beyond/en/publicacao/access-treatment-and-preventionbrazil-and-beyond, accessed 12 December 2011.
Correa, M. C. (2000) Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (London: Zed Books).
Correa, M. C. (2011) ‘Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing’, South Centre Research Paper, 41.
Drahos, P. (2008) ‘Does Dialogue Make a Difference? Structural Change and the Limits of Framing’, The Yale Law Journal, Pocket Part 117, 268–73.
Gomes, L. (2006) ‘Manager of Foreign Trade’, Febrafarma, personal interview, Sao Pablo, 6 June.
González, C. P. V., J. F. Fitzgerald and J. A. Z. Bermúdez (2006). ‘Definición de medicamento genèrico ¿un fin o un medio? Análasis de la regulación en 14 países de la Región de las Américas’, Pan American Journal of Public Health, 20, 314–23.
IMS Health (2010) Pharmerging Shake-up: New Imperatives in a RedefinedWorld (Norwalk, CT: IMS Health Incorporated).
Jaguaribe, R. (2005) Comments at the International Seminar on Contributions to the Development Agenda on Intellectual Property Rights, Maastricht, The Netherlands, 23–24 September. Confirmed in correspondence with author 18 December 2007.
Jawara, F. and A. Kwa (2003) Behind the Scenes at the WTO (London: Zed Books).
Jorge, F. M. (2004) ‘TRIPS-plus Provisions in Trade Agreements and Their Potential Adverse Effects on Public Health’, Journal of Generic Medicines, 1, 199–211.
Kesic, D. (2009) ‘Strategic Analysis of the World Pharmaceutical Industry’, Management, 14, 59–76.
Lustig, N. and I. F. Lopez-Calva (2010) Declining Inequality in Latin America: A Decade of Progress? (Washington, DC: Brookings Institution Press and UNDP).
Lybecker, M. K. and E. Fowler (2009) ‘Compulsory Licensing in Canada and Thailand: Comparing Regimes to Ensure Legitimate Use of WTO Rules’, The Journal of Law, Medicine and Ethics, 37, 222–39.
Moreira, M. M. (1990) ‘The Point of View of an Emerging Trading Nation: Brazil’ in J. Bhagwati and H. T. Patrick (eds) Aggressive Unilateralism: America’s 301 Trade Policy and the World Trading System (Ann Arbor: University of Michigan Press).
Nolan, P. (2001) China and the Global Business Revolution (London: Palgrave).
Nolan, P., D. Sutherland and J. Zhang (2002) ‘The Challenge of the Global Business Revolution’, Contributions to Political Economy, 21, 91–110.
Nunn, S. A., E. M. D. Fonseca, F. Bastos and S. Gruskin (2009) ‘AIDS Treatment in Brazil: Impacts and Challenge’, Health Affairs, 28, 1103–13.
Oliveira, A. M., J. A. Z. Bermudez, G. C. Chaves and G. Velasquez (2004) ‘Has the Implementation of the TRIPS Agreement in Latin America and the Caribbean Produced Intellectual Property Legislation that Favors Public Health?’, Bulletin of the World Health Organization, 82, 811–90.
Oliveira, N. B. D. (2006) Vice President of ABIFINA, personal interview, Rio de Janeiro, 26 June.
Orsi, L. F., B. Hasenclever, B. Fialho, P. Tigre and B. Coriat (2003) ‘Intellectual Property Right, Anti-AIDS Policy and Generic Drugs: Lessons from the Brazilian Public Health Program’ in J.-P. Moattli, B. Coriate, Y. Soutryran, T. Barnett, J. Dumoulin and V.-A. Fiori (eds) Economics of AIDS and Access to HIV/AIDS Care in Developing Countries, Issues and Challenges (Paris: Agence Nationale de Recherches sur le Sida).
Packenham, R. (1994) ‘The Politics of Economic Liberalization: Argentina and Brazil in Comparative Perspective’, Working Paper 206, Kellogg Institute for International Studies.
Presidencia da Republica (1993) Lei N°8.666 de Junho de 1993, Codigo Civil, http://www.planalto.gov.br/ccivil_03/Leis/L8666cons.htm, date accessed 10 December 2011.
Quental, C., J. Abreu, J. Bomtempo and C. Gadelha (2008) ‘Medicamentos genéricos no Brasil: impactos das políticas públicas sobre a indústria nacional’, Ciencia e Saúde Coletiva, 13, 619–28.
Roffe, P. (2004) ‘Bilateral Agreements and a TRIPS-plus World: the Chile–USA Free Trade Agreement. QIAP’,http://www.quno.org/geneva/pdf/economic/Issues/Bilateral-Agreements-and-TRIPS-plus-English.pdf/geneva/pdf/economic/Issues/Bilateral-Agreements-and-TRIPS-plus-English.pdf, date accessed 12 December 2011.
Sell, S. (1995) ‘Intellectua1 Property Protection and Antitrust in the DevelopingWorld: Crisis, Coercion and Choice’, International Organization, 49, 315–50.
Sell, S. (1998) Power and Ideas: North-Politics of Intellectual Property and Antitrust (Albany, NY: State University of New York Press).
Sweet, C. (2008) Indian Multinationals in Brazil: Emerging Multinationals in Emerging Markets. ‘Emerging Multinationals’: Outward Foreign Direct Investment from Emerging and Developing Economies (Copenhagen: Copenhagen Business School).
‘t Hoen, E. (2009) The Global Politics of Pharmaceutical Monopoly Power (Diemen, the Netherlands: AMB Publishers).
Tigre, P., J. E. Cassiolato, M. H. D. S. Szapiro and J. C. Ferraz (2002) ‘Institutional Change and Technology: Impacts of Deregulation on the National Innovation System’ in R. Bauman (ed.) Brazil in the 1990s: An Economy in Transition (Basingstoke:Palgrave).
Valente, V. (2006) ‘Generics in Latin America: An Analysis of the Brazilian Experience’, Journal of Generic Medicines, 4, 30–6.
Vara Federal do Rio Janeiro (2004) Ação ordinária n°2004.51.01.506840–0–37a
Vaughan, V. S. (2001) ‘Compulsory Licensing of Pharmaceuticals under TRIPS: What Standard of Compensation?’ Hastings International and Comparative Law Review, 25, 87–110.
Vijay, B. (2006) Country Manager, Wockhardt, personal interview, Sao Paulo, 18 May.
Vosgerau, M. Z., R. K. T. de Souza, and D. A. Soares. (2011) ‘Utilização de Genéricos em área de Atuação da Equipe de Saúde da Família em Município do Sul do Brasil’, Revista Brasileira de Epidemiologia, 14, 253–63.
Weyland, K. (1993) ‘The Rise and Fall of President Collor and Its Impact on Brazilian Democracy’, Journal of Interamerican Studies and World Affairs, 35(1), 1–37.
World Bank (2009) Brazil at a Glance. Development Economics LDB Database (Washington, DC: World Bank).
Yee, A. and J. Leahy (2008) ‘Shock in India over Ranbaxy Sale’, Financial Times, 11 June.
Editor information
Editors and Affiliations
Copyright information
© 2013 Cassandra M. Sweet
About this chapter
Cite this chapter
Sweet, C.M. (2013). The Political Economy of Pharmaceutical Production in Brazil. In: Löfgren, H., Williams, O.D. (eds) The New Political Economy of Pharmaceuticals. International Political Economy Series. Palgrave Macmillan, London. https://doi.org/10.1057/9781137315854_2
Download citation
DOI: https://doi.org/10.1057/9781137315854_2
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-32976-2
Online ISBN: 978-1-137-31585-4
eBook Packages: Palgrave Social Sciences CollectionSocial Sciences (R0)